Virazole is a nucleoside analogue indicated for severe lower respiratory infections due to respiratory syncytial virus (RSV) in hospitalized infant and young children. If a non-sterile drug with microbial contamination is inhaled into the airways, it may increase the risk of a respiratory infection. This risk may be greater in patients who are immunocompromised and are more susceptible.
The affected product is packaged in 100mL, 6g vials in 4-pack cartons. It contains Lot #340353F with an expiration date of Oct-2018, and was distributed in the United States and Australia.
For more information call (800) 321-4576 or visit FDA.gov.